Insurers rarely require prior authorization for opioids; court of appeals voids J&J win in Advil ads suit; new California law to address drug pricing
Too few of the billions of sites online are usable for disabled people, says AudioEye's CEO.
The rise of voice technology platforms and the connected home has turned the discussion of a brand's voice from metaphorical to physical.
The FDA approves first cancer biosimilar; it also approves Bayer's new lymphoma drug; clinical-trial participation for gynecological cancer drops
Facebook chief operating officer Sheryl Sandberg has said that in turbulent times the social network must do more than simply connect people.
One-third of clinical trials are never publicly registered; ICER revises PCSK9 cost-effectiveness analysis; flu shot linked to miscarriages
Aaron Sklar, formerly of Welltok, replaces Christine Armstrong, who moved on to a Silicon Valley health startup.
Guidemark Health's Tina Fascetti offers Medela's Katie Busse advice on being a working mother in healthcare marketing.
FDA closes pediatric study loophole; little evidence outcomes-based contracts are working; PBMs lobby against transparency efforts
Rosa talks about the wearable technology company's health and fitness plans and other areas of expansion.
The Royal College of Psychiatrists kicked off a six-week student recruitment campaign with a national media push and an emotive film voiced by patient testimony.
The drugmaker tapped Mark Salyer, who previously managed Teva's respiratory business.
Alexion to cut 600 jobs; Sage Therapeutics' experimental seizure drug fails to meet expectations; Apple is interested in medical and health activity
New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
The company is looking to expand the marketing of its blockbuster cosmetic drug.
Teva names new CEO; Allergan transfers Restasis patent to skirt competition; Google invests in oncology
Pfizer receives warning letter over EpiPen manufacturing; Opdivo kidney-cancer trial shows improved survival rates; cancer patients who discuss costs with physicians pay less
Incisive Health will next month welcome Francesca Scassellati Sforzolini as head of its Brussels office.
The OPDP has only issued two letters in 2017, compared to 11 last year.
The FDA halts IO-combo trial for Opdivo; Lilly slashes 3,500 jobs; new asthma drug could treat wide range of patients
The FDA warns drugmaker over opioid promotion; Watson may not be living up to the hype; Merck acquires immuno-oncology biotech
The federal government alleged that the drugmaker instructed its sales reps to convey messages to doctors that downplayed the drug's safety risks.
She is director of OTC brand marketing at Dr. Reddy's Laboratories.
Novartis CEO Joe Jimenez to step down; Sanofi ends R&D plans for Zika vaccine; oncologists still struggle to predict metastasis
No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar
By comparison, Omnicom's client roster includes less consumer goods companies compared to rivals WPP and Publicis Groupe.
Pfizer develops Minecraft version for kids with hemophilia; Lilly to resubmit baricitinib to the FDA; pricing expert says Novartis CAR-T value contract is 'progress'
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.
Why is revenue growth at some of the agency groups lagging forecasts for global ad expenditure?
Nonprofits receive FDA approval for Chagas drug; Gilead's buyout of Kite will put it back in pricing fray; most cancer patients don't receive fertility info
Consumers younger than the age of 45 were most likely to use an app developed by their health plan.
Drug ads make up to 38% of prime time commercials; Merck considers whether to pursue FDA approval for anacetrapib; BMS and Daiichi partner
The Havas Health & You agencies have reported some wins, however, including new business from Sanofi and Bristol-Myers Squibb.
Alone among the best-known social platforms, Snapchat has failed to generate much enthusiasm from pharma. Here's why — and here's why that may change.
Read the August 2017 issue in its entirety, including our recap of the MM&M Hall of Femme event.
Gilead to acquire Kite; the FDA issues fewest number of warning letters since 2008; the regulator approves BI's Humira biosimilar
Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.
The pharma company's Know Your Birth Control campaign is running for six months.
Google surveys for depression; patients with diabetes that adhere to their regimen had fewer ER visits; Biogen, Samsung scores Humira biosimilar approval in EU
News-style segments for MTV's Video Music Awards expose how brands have marketed cigarettes to already vulnerable groups.
Amgen publishes study assessing cost-effectiveness of Repatha; Brilinta reduces death in patients with heart-attack history; Roche drug gets priority review
The agency appointed Sonja Foster-Storch, previously president of McCann Echo, to fill a role that has been vacant since 2016.
Business analysts have generally agreed that WPP's half-year earnings fell below expectations given recent market commentary, but have offered mixed guidance going forward.
Doctors fret about price of Novartis' experimental CAR-T therapy; study finds digital pillboxes don't improve adherence; India awards Pfizer vaccine patent
He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie's Humira, which he helped commercialize.
Novartis launches MS study with Apple's ResearchKit; the FDA considering limiting risk info in drug ads; J&J loses baby powder lawsuit
She is working on commercial partnerships for the point-of-care company.
Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?
CVS Health's decision to remove Lilly's Jardiance for J&J's Invokana has analysts wondering if exclusive pricing contracts could shape the future of the GLP-1 class.
The FDA approves Ironwood's gout drug; GSW names new president; Samsung and Takeda to partner on biologic development
Procter & Gamble has revived the campaign with a new spot tackling the lack of confidence during puberty.
Condé Nast, Time Inc., and Vice Media have all recently launched health content businesses.
WPP was added to Sanofi's creative agency roster and GroupM's Mindshare is the drugmaker's new global media agency of record.
Lawmakers to investigate pricing of MS drugs; Mylan will pay $465 million to resolve EpiPen allegations; the FDA approves Pfizer's new cancer drug
Express Scripts to limit opioid coverage; Novo's diabetes drug lowers glucose levels in trial; startup aims to give doctors access to a patient's total costs
The lobbying group said it's unclear what the agency's goal is with this research and how it promotes public health.
Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
Johnson & Johnson has breached the U.K.'s drug regulation code in three places in promotions for smoking cessation product Nicorette.
Gottlieb criticizes drugmakers for 'gaming the system' on generics; investors ignore Trump's pharma criticism; docs are more supportive of single payer
Both positions were newly created as the agency has grown over the past year.
It's not often that pharmaceutical companies are held up as examples of morality or leadership to the general public.
Pfizer accuses J&J of limiting biosimilar uptake; Trump again criticizes high drug prices; WebMD to reposition site to help consumers manage their health
What's holding back value-based pricing deals from moving beyond the pilot phase?
Merck CEO leaves Trump's manufacturing council over Charlottesville response; researchers struggle to fill clinical trials for IO drugs; Roche shareholders sue over top-line results
Accenture Interactive claims it is building the first global "experience agency of record" and that it can cater for the needs of brands better than traditional agency holding companies.
Calman is joining the technology company as VP of comms for Watson Health.
The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.
The goal is to further cement point of care as a mainstream media channel.
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.
Egalet slashes workforce in favor of opioid education; Novo's experimental obesity drug reports positive results; Trump declares opioid crisis a national emergency
One in 12 docs took payments from opioid makers; hospitals cut use of Isuprel and Nitropress after price hikes; AI helping develop ALS drugs
Patients are demanding more of their healthcare experience — and that includes from their healthcare providers, according to two new surveys.
A mentor once told him to keep learning and stay out of his comfort zone.
The FDA on pace for record generic drug approvals; CVS Health CEO doubts Amazon's entrance to pharmacy market; Sanofi to develop cancer immunotherapy
In a follow-up to last year's media report, the Association of National Advertisers details "dysfunction" and rigged bids.
Pharma has more or less ignored the social-blog hybrid Tumblr, with the number of programs using it countable on a single hand. That's about to change.
They are using social media campaigns, apprentice programs, and hands-on internships to recruit young, innovative talent right out of school.
A shorter list of risks in TV ads helps consumer comprehension; medical-school choice affects prescribing patterns; reps often show docs the same info
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
O'Connor Vos has served as CEO of the WPP Health & Wellness agency since 1994.
The drugmaker began advertising for Rhofade on Facebook in early August.
Insurers deny coverage of generic drugs; Teva to lay off 7,000 employees; Shkreli convicted of securities fraud
Participants in this roundtable explore how digital forms of data are poised to illuminate the reimbursement pathway, as market access gets its closeup.
AbbVie's new HCV drug is cheaper than Gilead's Harvoni; Lilly's experimental migraine drugs beats placebo; Fitbit to launch smartwatch
She will also continue to serve as president of the Astellas U.S.A. Foundation.
FDA committee votes against J&J arthritis drug; scientists successfully edit genes; Shire mulls ADHD spin off
Former Edelman executive Mary Corcoran replaces Annalise Coady, who becomes president of W2O EMEA.
CVS Health will remove Lilly's Jardiance in favor of J&J's Invokana.
Celgene and Agios secure FDA approval for AML drug Idhifa; GSK hires chief digital and technology officer; Pfizer wants tax reform before M&A engagement
Susan Sweeney has earned a reputation for such pragmatism and attentiveness to the things that really matter.
Read the 2017 Agency Issue in its entirety.
Express Scripts removes 64 branded drugs from 2018 formulary; wearable market can regain momentum, analysts say; FDA accepts Herceptin biosimilars for review
Meet 13 of our 16 Hall of Femme honorees.
FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Frustrated by its inability to empathize with patients, pharma has turned to tech to teach providers and caregivers what illness really feels like.
A particular focus is put on the emerging research about cannabis and its benefits for the human body.
Drugmakers inconsistently share clinical trial data; AstraZeneca's share price falls after Mystic results; some pregnancy apps share info with marketers